Skip to main content

Table 1 Patient and treatment characteristics in the EFRT (A) and WPRT (B) groups

From: Dosimetric predictors of nephrotoxicity in patients receiving extended-field radiation therapy for gynecologic cancer

(A)

EFRT patient characteristics

Age (years)

 

Mean (SD)

54.8 (13.8)

Median (range)

52 (35–85)

Primary cervical cancer

32 (94%)

Post-operative recurrent cervical cancer

1 (3%)

Primary endometrial cancer

1 (3%)

Medical history affecting renal function

None

25 (74%)

Hypertension

5 (15%)

Hypercholesterolemia

1 (3%)

Diabetes and hypercholesterolemia

1 (3%)

Diabetes, hypertension, and hypercholesterolemia

1 (3%)

Nephrotic syndrome

1 (3%)

Pre-treatment baseline creatinine clearance

Mean (SD)

86.6 mL/min (20.5)

Median (range)

84 mL/min (57.8–149.8)

Histology

Squamous cell carcinoma

28 (82%)

Adenocarcinoma

6 (18%)

Para-aortic node positive on 18F-FDG-PET/CT

Yes

32 (94%)

No

2 (6%)

External beam radiotherapy

Box field EFRT

13 (38%)

Coplanar EF-IMRT

15 (44%)

Non-coplanar EF-IMRT

6 (18%)

EFRT dose (Gy)

Median (range)

55.8 (55.8–59.4)

(B)

WPRT patient characteristics

Age (years)

Mean (SD)

57.1 (12.9)

Median (range)

56 (31–85)

Primary cervical cancer

54 (84%)

Post-operative cervical cancer

10 (16%)

Medical history affecting renal function

None

49 (77%)

Hypertension

6 (9%)

Hypercholesterolemia

5 (8%)

Diabetes and hypertension

2 (3%)

Diabetes

1 (2%)

Hypertension and hypercholesterolemia

1 (2%)

Pre-treatment baseline creatinine clearance

Mean (SD)

83.4 mL/min (19.1)

Median (range)

80.8 mL/min (47.6–152.1)

  1. EF-IMRT extended-field intensity-modulated radiation therapy, EFRT extended-field radiation therapy, 18F-FDG-PET/CT positron emission tomography with 18F-labeled fluoro-2-deoxyglucose/computed tomography, SD standard deviation, WPRT whole-pelvis radiation therapy